Cookie Control

This site uses cookies to store information on your computer.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

By using our site you accept the terms of our Privacy Policy.

(One cookie will be set to store your preference)
(Ticking this sets a cookie to hide this popup if you then hit close. This will not store any personal information)

US Purchases $290 Million Worth Of Drug For Use In Nuclear Emergencies

"The Department of Health and Human Services (HHS) says it has spent $290 million on a drug to treat radiation sickness in the event of a nuclear emergency.

The HHS Administration for Strategic Preparedness and Response announced in a Tuesday release that it bought the drug Nplate from Amgen USA Inc. “as part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies.”

Acute Radiation Syndrome, caused by exposure to a high dose of radiation, can cause a range of symptoms. Severe cases can wreak devastating effects on the body, including destruction of bone marrow and internal bleeding, according to the Centers for Disease Control and Prevention.  

Nplate, which can be used for both adults and children, is aimed at reducing the uncontrolled bleeding often caused by radiation."

Julia Mueller reports for The Hill October 6, 2022.

Source: The Hill, 10/07/2022